Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Fineline Cube Apr 21, 2026
Company Drug

AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics

Fineline Cube Feb 26, 2024

AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA...

Company Deals

b-ONE Ortho Partners with THINK Surgical to Expand MOBIO Knee System in U.S. Market

Fineline Cube Feb 26, 2024

b-ONE Ortho Corp., a developer of artificial joint replacements with operations in the U.S. and...

Company Deals

CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System

Fineline Cube Feb 26, 2024

CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a...

Company Deals

Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal

Fineline Cube Feb 26, 2024

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...

Policy / Regulatory

Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area

Fineline Cube Feb 26, 2024

The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...

Company Deals Digital

Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations

Fineline Cube Feb 26, 2024

Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees...

Company Drug

Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension

Fineline Cube Feb 26, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...

Company Deals

Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries

Fineline Cube Feb 26, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...

Policy / Regulatory

Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits

Fineline Cube Feb 26, 2024

The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...

Company Drug

GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma

Fineline Cube Feb 26, 2024

GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...

Company Drug

Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC

Fineline Cube Feb 26, 2024

South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...

Company Drug

Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China

Fineline Cube Feb 26, 2024

The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...

Company Deals

Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Drug

Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development

Fineline Cube Feb 23, 2024

Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...

Company Drug

Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio

Fineline Cube Feb 23, 2024

Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Adjuvant Therapy Clinical Study of Adebrelimab in NSCLC

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval...

Company Drug

BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy

Fineline Cube Feb 23, 2024

BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120...

Company Drug

Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study

Fineline Cube Feb 23, 2024

Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...

Company Drug

Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies

Fineline Cube Feb 23, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Posts pagination

1 … 386 387 388 … 654

Recent updates

  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.